Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
COSTS AND EXPENSES:        
Research and development $ 21,976 $ 16,579 $ 48,487 $ 35,001
General and administrative 7,026 6,757 14,417 14,771
Costs and Expenses 29,002 23,336 62,904 49,772
Operating loss (29,002) (23,336) (62,904) (49,772)
Interest and other income, net 646 196 1,543 215
Net loss (28,356) (23,140) (61,361) (49,557)
Preferred stock deemed dividend 4,255 4,255
Net loss available to common stockholders $ (28,356) $ (27,395) $ (61,361) $ (53,812)
Net loss per common share, basic $ (2.68) $ (7.64) $ (5.88) $ (17.28)
Net loss per common share, diluted $ (2.68) $ (7.64) $ (5.88) $ (17.28)
Weighted average common shares outstanding, basic 10,587,096 3,584,699 10,428,678 3,113,965
Weighted average common shares outstanding, diluted 10,587,096 3,584,699 10,428,678 3,113,965